GlaxoSmithKline ( (GB:GSK) ) just unveiled an announcement.
GlaxoSmithKline (GSK) has announced the purchase of 847,000 of its own ordinary shares as part of its ongoing buyback program. The shares, acquired through Citigroup Global Markets Limited, will be held as treasury shares, contributing to a total of 184,789,390 shares in treasury. This move is part of a non-discretionary agreement initiated on 24 February 2025, and since then, GSK has repurchased a total of 15,719,087 shares. The buyback program is a strategic effort to manage the company’s capital structure and potentially enhance shareholder value.
More about GlaxoSmithKline
YTD Price Performance: 10.81%
Average Trading Volume: 8,850,404
Technical Sentiment Signal: Strong Sell
Current Market Cap: £60.01B
For a thorough assessment of GSK stock, go to TipRanks’ Stock Analysis page.